Special Issue "Oncolytic Viruses and Combinatorial Immunotherapy for Cancer"
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: 30 May 2024 | Viewed by 62
Special Issue Editors
Interests: oncolytic virus; poxviruses; cancer immunotherapy; cancer immunology; oncoimmunology; molecular targeted therapy; combinatorial therapy for cancer
Special Issues, Collections and Topics in MDPI journals
Interests: cell signaling; cell migration; cytokine gene expression; HIV; poxviruses; vaccines; viral vectors; virus–host interactions
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Oncolytic viruses (OVs) are developed as tools for novel cancer therapies. In recent years, investigators have started to realize that the indirect antitumor activity of viruses beyond direct oncolysis is a vital contributor to therapeutic efficacy. OV-induced antitumor immunity plays an important, sometimes essential, role in OV-mediated therapeutics for cancer.
OVs modulate the tumor microenvironment to favor antitumor immunity. Their ability to turn cold tumors immunologically hot is a unique property that makes OVs highly useful agents in combinatorial approaches for cancer immunotherapy.
We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-advancing field of biomedicine.
The submission of articles addressing (i) the mechanisms of action of OVs, (ii) genetic modifications of OVs for improving their efficacy and safety, (ii) the delivery of OVs, (iv) host responses to OVs and (v) studies with combinatorial approaches is strongly encouraged.
Dr. Zong Sheng Guo
Dr. Michael H. Lehmann
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oncolytic virus
- antitumor immunity
- cold tumor
- tumor antigen
- cancer vaccine
- immunotherapy
- combinatorial therapy
- immune checkpoint blockade
